RE:RE:Votes"Gilles has essentially given up on CEAPRO by selling it for next to nothing"
H.C. Wainwright had a US$15 target on AEZS which is about ~C$100 million in market cap. That value is likely substantially driven by the diagnostic test. As a merger of equals, with shareholders of each company controlling 50% of the new company, CZO can be thereby seen as being valued similarly. Gilles, as a member of AEZS's Board of Directors, has an edge in terms of understanding the deals AEZS has been working on for its tests, etc. An anticipated diagnostic deal and PGX deal can help realize the value and the combined resources can accelerate CZO's plan.
“We are thrilled with this exciting transaction to merge with Aeterna and combine two complementary companies and teams, in support of our plan to drive significant growth,” said Ronnie Miller, Chairman of Ceapro.